Brilinta + Placebo
Phase 3Withdrawn 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease
Trial Timeline
Jun 30, 2020 → Oct 10, 2022
NCT ID
NCT04293172About Brilinta + Placebo
Brilinta + Placebo is a phase 3 stage product being developed by AstraZeneca for Sickle Cell Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04293172. Target conditions include Sickle Cell Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04293172 | Phase 3 | Withdrawn |
Competing Products
20 competing products in Sickle Cell Disease